Latest News

Biotech Stock News: Nova Mentis (CSE: NOVA) and University of Central Florida to Develop Saliva Serotonin Assay

Vancouver, British Columbia – June 9, 2022 (Newsfile Corp.) ( Newswire) Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that it has signed a research agreement with the University of Central Florida (UCF) Research Foundation to develop a saliva serotonin assay.

Dr. Kiminobu Sugaya, a Professor and Head of Neuroscience in the Burnett School of Biomedical Science at UCF, will measure serotonin levels in the saliva samples collected as part of the recently launched NOVA autism spectrum disorder (ASD) observational study.

“This scientific relationship with Dr. Sugaya and UCF will allow the development of a potential groundbreaking serotonin assay that will measure levels of serotonin that is contained within vesicles, or small fluid-filled sacs, that migrate through the blood brain barrier,” stated Dr. Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board. “Serotonin is a key neurotransmitter that has been implicated in the development of autism spectrum disorder and the ability to measure its levels in a patient’s saliva will potentially assist NOVA in predicting disease development and in establishing specific treatable subsets of diseases that makeup the ‘spectrum’ called autism. Moreover, the establishment of this biomarker in the saliva of ASD patients will allow healthcare professionals to monitor levels of serotonin and assess the efficacy of various treatment programs.”

NOVA has recently launched an IRB approved ASD observational study in North America and specimens of a patient’s saliva and buccal check cells are being collected. The cheek cells, in addition to measurement of serotonin saliva levels, will allow study of the neuroinflammatory mRNA genetic profile of ASD patients. The research objective is to develop a genetic neuroinflammatory and serotonin data bank that will help establish a “Diagnostic Index” – an objective set of tools that helps to differentiate subtypes of ASD and the major genetic subset of ASD, fragile X syndrome (FXS), and to develop more accurate methods of diagnosis and treatment.

Collected data will be analyzed using customized machine learning algorithms and used to guide design of upcoming clinical trials that will test the efficacy of psilocybin-based therapeutics in ASD and FXS.

NOVA is currently enrolling participants in the study and is aiming to recruit at least 300 qualifying participants; 200+ ASD/FXS patients and 100+ neurotypical controls.

For more information on this research, visit: To express your interest in participating in this study, please complete the enrollment form.

If you have any questions, email us at or call us at 1-888-505-NOVA (6682).

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of Fragile X Syndrome (FXS).

Our goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.

For further information on the Company, please visit or email

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

More Info:

This news is published on the Newswire – a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy: – investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Buy a biotech guest post on

What's your reaction?

In Love
Not Sure

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:Latest News